Practicing clinicians come across uses of pharmacologic agents that may not always be listed in the usual references. For example, glycerin injection for nerve block, H2 antagonists in colorectal cancer, or colchicine for systemic sclerosis may represent novel, hard-to-find clinical applications. If you have encountered a new and/or unusual use of a drug, submit the information to this Hospital Pharmacy feature. Send three copies, double-spaced, 1,000 word or less, to: Thomas G. Bur-nakis, PharmD, Baptist Medical Center, 800 Prudential Drive, Jacksonville, FL 32207. Please include a list of “key words” that an individual might logically look for in an index when searching for this information.
Get full access to this article
View all access options for this article.
References
1.
Anon.Drugs for non-HIV infections. Medical Letter.1997; 39(1006): 69–76.
2.
GrellierL., MutimerD., AhmedM.Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet.1996; 348: 121.2–15.
3.
BainB.G., KnetemanN.M., MaM.M.Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation.1996; 62(10): 1456–62.
4.
LaiC.L., ChingC.K., TungA.K.Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hap-atitis B surface antigen carriers. Hepa-tology.1997; 25: 241–4.
5.
DienstagJ.L., PerrilloR.P., SchiffE.R.A preliminary trial of lamivudine for chronic hepatitis B infections. N Engl J Med.1995; 333: 1657–61.
6.
NevensF., MainJ., HonkoopP.Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study. Gastroenterol.1997; 113: 1258–63.
7.
LaiC.L., ChienR.N., LeungN.W.Y.A one-year trial of lamivudine for chronic hepatitis B. N Eng J Med.1998; 339(2) 61–7.
8.
HonkoopP., deManR.A., HeijtinkR.A.Hepatitis B reactivation after lamivudine. Lancet.1995; 346: 1156–7.
9.
LeeW.M.Hepatitis B virus infection. N Engl J Med.1997; 337(24): 1733–45.
10.
HoffnagleJ.H., DiBisceglieA.M.The treatment of chronic viral hepatitis. N Engl J Med.1997; 336(5): 347–56.
11.
RobinsonW.S.Hepatitis B virus and hepatitis D virus. In: MandellG.L., Ben-netJ.E., DolinR., eds. Principles and Practice of Infectious Diseases.4th ed.New York, NY: Churchill Livingstone;1995; 1406–39.
12.
AlterM.J., MastE.E.The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am.1994; 23: 437–55.
13.
HoofnagleJ.H., BisceglieA.M.Serologic diagnosis of acute and chronic viral hepatitis. Sem Liv Dis.1991; 11: 73–83.
14.
HoofnagleJ.H.A short course of prednisolone in chronic type B hepatitis. Ann Int Med.1986; 104: 12.
15.
WooM.H., BurnakisT.G.Interferon alfa in the treatment of chronic hepatitis B and C. Ann Pharmacother.1997; 31: 330–7.
16.
OmataM.Treatment of chronic hepatitis B infection. N Engl J Med.1998; 339(2): 114–5.
17.
BartholomewM.M., JansenR.W., JeffersL.G.Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet.1997; 349: 20–22.
18.
TipplesG.A., MaM.M., FischerK.P.Mutation in HBV RNA-dependent polymerase confers resistance to lamivudine in vivo. Hepatology.1996; 24(3): 714–7.
19.
MarinosG., NaoumovN.V., WilliamsR.Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology.1996; 24: 991–5.
20.
WoltersL.M.M., HonkoopP., deManR.A.Famciclovir treatment in lamivudine resistant chronic hepatitis B patients [abstract]. J Hepatol.1998; 28: 113.
21.
JochumC., HoltmannG., HoffmannP.Ganciclovir and lamivudine combination therapy after orthotopic liver transplantation [abstract]. Gastroenterol.1998; 114: L0279.
22.
MarkowitzJ.S., MartinP., ConradA.J.Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immunoglobulin [abstract]. Hepatology.1997; 26: 152A.
23.
BenhamouY., BohinE., Lunel-Fabi-aniF.Efficacy of lamivudine on replication of hepatitis B in HIV-infected patients. Lancet.1995; 345: 396–7.
24.
MutimerD., NaoumovN., HonkoopP.Combination alpha-interferon and lamivudine therapy for alpha-interferon resistant chronic hepatitis B infection: Results of a pilot study. J Hepatol.1998; 28: 923–9.
25.
JohnsonM.A., HorakJ., BreuelP.The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J. Clin Pharmacol.1998; 54: 363–6.
